I'm LongbridgeAI, I can summarize articles.RBC Capital Markets warns Gilead Sciences faces a potential threat from in vivo CAR-T technology, which could impact 10-15% of its future revenue. While Gilead's ex vivo franchise is expected to grow, reaching over $4 billion by decade-end, in vivo therapy offers a broader patient eligibility alternative. RBC maintains a sector perform rating with a $122 price target, noting Gilead's acquisitions of Interius and collaboration with Pregene to integrate in vivo platforms.
11:00 AM EDT, 06/08/2026 (MT Newswires) -- Gilead Sciences ( GILD ) faces a potential threat from in vivo CAR-T, an early-stage technology that could transform the cell therapy space and impact 10% to 15% of Gilead's future revenue, RBC Capital Markets said Monday.
Analysts expect Gilead's ex vivo CAR-T franchise to become an increasingly meaningful revenue driver. Its commercial Yescarta/Tecartus cell therapy portfolio generated $1.8 billion in 2025, and despite headwinds from bispecific competition and challenges scaling beyond academic centers, a gradual recovery is expected as anito-cel launches and ramps, the firm said. Total cell therapy sales could potentially exceed $4 billion around the end of the decade, the brokerage said.
While there is room for organic growth of the cell therapy franchise, management believes only 10% to 20% of patients are eligible to actually receive CAR-T, while in vivo cell therapy presents a better alternative, the brokerage added.
The company's in vivo focused transactions include the Interius BioTherapeutics acquisition, bringing a lentiviral vector-based in vivo CAR-T platform with preclinical proof of concept data and intellectual property now integrated into Gilead, and the Pregene collaboration, a complementary in vivo vector delivery platform adding intellectual property breadth and a distinct design approach, according to the note.
RBC kept a sector perform rating on Gilead Sciences ( GILD ) with a price target of $122.
Price: 128.63, Change: -0.53, Percent Change: -0.41
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.